肿瘤灌注PET成像:潜在的癌症生物标志物?
本文综述了肿瘤灌注PET成像的多种方法,包括15O-water PET作为绝对定量金标准、高首过摄取示踪剂提供相对灌注定量,以及18F-FDG多时间点成像的替代策略。尽管存在示踪剂生产、图像处理、监管审批等障碍,这些障碍正在被克服,未来有望将全身15O-water灌注PET与18F-FDG-PET同步进行,结合绝对肿瘤血流量与糖酵解信息辅助预后和临床决策。
要点
- 15O-water PET是组织灌注绝对定量的公认金标准,可用于肿瘤。
- 高首过摄取示踪剂提供高对比度图像但仅为相对灌注定量。
- 18F-FDG多时间点成像非灌注专用,但具有可及性和报销优势。
核心结论
- PET肿瘤灌注成像有望成为标准临床实践,未来可能实现全身15O-water灌注PET与18F-FDG-PET单次成像同步进行。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- 15O-water PET是正常组织和包括癌症在内的多种病理条件下组织灌注绝对定量的公认金标准。
- 高首过摄取示踪剂策略产生视觉上高对比度图像,提供相对而非绝对灌注定量。
- 18F-FDG等多时间点成像并非专门针对灌注优化,但具有可及性、便利性和报销优势。
关键数值与推荐
- 15O-water PET被认定为组织灌注绝对定量的金标准。
- 高首过摄取示踪剂策略提供相对灌注定量而非绝对定量。
临床怎么用
- 肿瘤灌注PET测量可用于改善病灶视觉检测、鉴别良恶性、评估肿瘤侵袭性、识别缺血及缺氧、评估治疗反应。
- 未来可能将绝对肿瘤血流量与糖酵解信息结合,为预后和临床决策提供互补信息。
局限性
- 示踪剂生产和分销、图像处理、患者身体覆盖范围、临床验证、监管审批和报销以及可行的临床工作流程等障碍阻碍了PET肿瘤灌注的常规使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Perfusion, as measured by imaging, is considered a standard of care biomarker for the evaluation of many tumors. Measurements of tumor perfusion may be used in a number of ways, including improving the visual detection of lesions, differentiating malignant from benign findings, assessing aggressiveness of tumors, identifying ischemia and by extension hypoxia within tumors, and assessing treatment response. While most clinical perfusion imaging is currently performed with CT or MR, a number of methods for PET imaging of tumor perfusion have been described. The inert PET radiotracer 15O-water PET represents the recognized gold standard for absolute quantification of tissue perfusion in both normal tissue and a variety of pathological conditions including cancer. Other cancer PET perfusion imaging strategies include the use of radiotracers with high first-pass uptake, analogous to those used in cardiac perfusion PET. This strategy produces more visually pleasing high-contrast images that provide relative rather than absolute perfusion quantification. Lastly, multiple timepoint imaging of PET tracers such as 18F-FDG, are not specifically optimized for perfusion, but have advantages related to availability, convenience, and reimbursement. Multiple obstacles have thus far blocked the routine use of PET imaging for tumor perfusion, including tracer production and distribution, image processing, patient body coverage, clinical validation, regulatory approval and reimbursement, and finally feasible clinical workflows. Fortunately, these obstacles are being overcome, especially within larger imaging centers, opening the door for PET imaging of tumor perfusion to become standard clinical practice. In the foreseeable future, it is possible that whole-body PET perfusion imaging with 15O-water will be able to be performed in a single imaging session concurrent with standard PET imaging techniques such as 18F-FDG-PET. This approach could establish an efficient clinical workflow. The resultant ability to measure absolute tumor blood flow in combination with glycolysis will provide important complementary information to inform prognosis and clinical decisions.
引用
- Johnson GB, Harms HJ, Johnson DR, et al. PET Imaging of Tumor Perfusion: A Potential Cancer Biomarker? Semin Nucl Med. 2020. PMID: 33059824. doi:10.1053/j.semnuclmed.2020.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。